Unlicensed Medicines Access Program Types and Regulatory Frameworks

A program is called a named patient program, a managed access program or an early access program largely according to the label its sponsor prefers, but what actually determines how supply works is the regulatory trigger that makes the supply lawful in a given country.

That trigger is usually one of four things: a physician request for an individual patient, a regulator's decision to allow supply before authorisation, a payer's decision to fund supply during the period before reimbursement, or an emergency declaration that permits import of a product not otherwise available.

Anyone assessing the unlicensed medicines and managed access programs market therefore benefits from starting with the trigger, since two programs with different labels can work almost identically and two programs with the same label can work very differently from one country to another.

The trigger sets who must give permission. In some systems the treating physician alone takes responsibility for the request, in others a national regulator or an ethics committee must approve each case, and in a few a manufacturer must also agree to supply.

It also sets what documentation travels with the shipment. Typical items include a prescriber statement of need, evidence that no authorised alternative is available, import permits, product quality documentation and a plan for reporting adverse events back to the manufacturer.

The trigger affects who pays. A named patient request is often paid for by the hospital or by the patient's insurer, while a program organised by a manufacturer may supply product free of charge during an early phase and move to paid supply as a reimbursement decision approaches.

Because these conditions differ by country, a single global program is in practice a bundle of national programs that share a product and a protocol but not a legal basis, and the administrative cost of running it rises with every country added.

Program labels are still useful as a shorthand. They tell a hospital pharmacist or a medical affairs team roughly who initiated the supply, how many patients are involved and how long the arrangement is expected to last, even if they do not describe the legal detail.

This page describes access programs as structural channels for supplying medicines and as market segments. It makes no statement about whether any medicine is effective or safe, and it does not offer guidance on prescribing or on patient eligibility.

Named Patient Programs and Managed Access Programs

A Named Patient Program (NPP) supplies a specific unlicensed medicine to a specific patient at the request of a treating physician. It is the oldest and most widely recognised access route, and in many countries the legal basis is a long-standing exemption that allows a physician to obtain a product that has no local authorisation.

The defining feature is that the request names an individual. Each supply decision is made case by case, the quantity is tied to that patient's need, and the physician accepts professional responsibility for the choice of product.

A Managed Access Program (MAP) works the other way round. A manufacturer, or a partner appointed by the manufacturer, designs the program in advance, defines the eligible countries, sets the criteria for participation and then manages requests as they arrive from physicians in those countries.

Managed access programs are usually governed by a written protocol and are administered through a central team that handles physician enquiries, documentation checks, import permits, shipment, pharmacovigilance and reporting back to the sponsor.

The practical difference lies in who carries the administrative load. In a pure named patient request the physician and hospital pharmacy do most of the work, while in a managed access program the sponsor or its partner takes on much of it and the hospital interacts with a single contact.

The two models also tend to serve different product categories supplied through these programs, with managed access more common for therapies that a manufacturer wants to supply consistently across several countries and named patient requests more common for isolated needs.

Many programs combine features of both. A manufacturer may run a managed access program as the main route and still accept individual named patient requests from countries outside the defined list, which means the two models coexist in practice.

Both models depend on pharmacovigilance. The sponsor remains responsible for collecting and reporting safety information from the program, which is a major reason why manufacturers use specialist providers rather than handling requests informally.

Terms are also used differently across the industry. Some organisations use managed access as a broad label that includes named patient supply, while others reserve it for formal manufacturer-led programs, so documents from different sources should be read with the definition in mind.

Compassionate Use and Expanded Access Programs

Compassionate use programs and expanded access programs are linked by the type of situation they address. Both are intended for patients with serious or life-threatening conditions for whom no satisfactory authorised option exists and who cannot take part in a clinical trial.

The two names reflect regional vocabulary more than a different mechanism. Compassionate use is the term used in European legislation, while expanded access is the term used by the United States regulator, and each framework sets its own conditions for who may apply and who must authorise.

A distinguishing feature of both is that the medicine is typically still an investigational product or one with a pending marketing application. This separates them from named patient supply, which more often involves a product that is authorised somewhere else in the world.

Programs can be designed for a single patient, for a small group with similar needs or for a wider population, and the larger the group the more closely the program resembles a managed access program in its administration and governance.

Regulators attach conditions to these programs. Common requirements include a documented unmet need, agreement from the manufacturer to supply, ethics committee or regulatory review, informed consent from the patient and a commitment to report safety events.

Sponsors generally approach these programs as part of a broader development and launch plan. A decision to offer compassionate use or expanded access has consequences for clinical development, regulatory strategy and supply planning, so it is normally taken at a senior level.

Supply arrangements are often free of charge for the product itself, with the sponsor bearing the cost, although some jurisdictions allow cost recovery within defined limits. How costs are allocated varies by country and by program.

Where demand for a compassionate use program grows, a sponsor may convert it to a different model, for example an early access program with a reimbursement mechanism, in order to continue supplying patients on a more sustainable footing.

Early Access, Temporary Authorization and Emergency Import Programs

Early access programs allow a medicine to be supplied before full marketing authorisation, but with a closer link to the eventual commercial launch than compassionate use programs have. Some frameworks attach reimbursement to the early access period, which gives the sponsor a route to paid supply.

Temporary authorization programs are a related mechanism in which a regulator grants a time-limited permission for a product to be supplied under defined conditions. The permission may apply to a named product, a named indication or a named group of patients, and it normally ends when a full decision is made.

Emergency import programs address a different situation: a product that is not authorised in a country but is needed urgently, for instance because a licensed alternative has been withdrawn or has run short. The importing hospital or government body requests permission to bring in the product from abroad.

These routes are rarely run by manufacturers alone, and many sponsors rely on companies that manage these programs to handle regulatory submissions, import documentation, shipment and safety reporting in each country.

Early access programs often involve a formal application and a defined evaluation by a national body. Eligibility may be limited to products that meet criteria such as a serious condition, an unmet need and a plausible benefit, which are set by the regulator and not by the sponsor.

For a sponsor, an early access program can serve several purposes. It supplies patients before launch, builds experience with the product among physicians and hospital pharmacists, and gives the company information about how supply will work after authorisation.

Temporary authorization and emergency import routes tend to be shorter and more reactive. They may be opened for a specific situation and closed when it ends, which makes them harder to plan for but important to understand for any manufacturer with products that may be needed at short notice.

All three program types carry administrative requirements that are similar to those of managed access programs, including documentation of need, import control, product handling and safety reporting, although the exact forms differ by country.

The boundaries between program types are not always clear. A temporary authorization may be implemented through an early access program, and an emergency import may use the machinery of a named patient request, so the labels describe the main feature rather than a separate system.

Compassionate Use, Expanded Access, Early Access Reimbursement and Emergency Access Markets

The report groups national environments into four regulatory framework categories according to which access route dominates: compassionate use regulated markets, expanded access markets, early access reimbursement markets and emergency access markets.

Compassionate use regulated markets are countries where a formal legal framework governs compassionate supply, usually through a regulator or an ethics review process. Manufacturers operating in these markets must meet explicit conditions on application, approval and reporting.

Expanded access markets are those where the principal route for pre-authorisation supply is an expanded access framework run by a national regulator, which sets rules for individual patient requests, intermediate-size groups and wider treatment protocols.

Early access reimbursement markets are countries in which pre-authorisation supply can be funded by a payer or national health system, which turns early access from a cost carried by the sponsor into a route with a defined commercial dimension.

Emergency access markets are countries where supply of unauthorised products depends mainly on emergency import or special authorisation procedures, often because the formal programs found elsewhere are less developed or because the need is driven by shortages.

A single country can sit in more than one category. A national health system may allow early access with reimbursement for some products, expanded access for others and emergency import in a shortage, and a manufacturer needs to know which route applies to which product.

Frameworks also change over time. Several countries have introduced or revised early access schemes in recent years, and sponsors that planned around one set of rules sometimes find that a new framework changes the options available to them.

For commercial planning, the framework category influences the type of partner a manufacturer chooses. A reimbursement-linked early access market may require strong market access capability, while an emergency access market may place more weight on logistics speed and documentation.

Understanding these categories helps place programs in context, but it does not replace country-specific regulatory advice, which sponsors obtain from qualified regulatory professionals before starting any program.